Natco Pharma stock corrected sharply due to weak Q3 results, but future opportunities like semaglutide offer hope.

NATCO Pharma stock has declined 34% over six days due to disappointing Q3 FY25 results, including a 37.4% revenue drop and a ...

NATCO Pharma shares tumbled 10% on Friday, extending a two-day slump to 28% after weak Q3 results and a target price cut by ...

NATCO Pharma faced a sharp decline, with a 37.75% drop in net profit in Q3 to Rs 132.4 crore due to lower formulation exports ...

During the quarter, contribution from the export formulation business was lower; however, the company expects healthy ...

Natco Pharma Ltd shares tanked during the early trading session on Thursday, February 13, 2025, after it announced weak third ...

Revenue decreased by 37.41% YoY & profit decreased by 37.47% YoY, profit at ₹133 crore and revenue at ₹474.8 crore.

Natco Pharma shares nosedived today. Its results were impacted by a sharp decline in the export formulation business.

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

The stock plunged 10.80 per cent to hit a day low of Rs 868.25. At this price, it has tumbled 28.63 per cent in two trading ...

Image Source : PIXABAY The counter opened gap down with a loss of 18.96 per cent.

Natco Pharma's Q3 earnings were heavily dented by a sharp drag in its export formulations segment, which accounted for 44 ...